Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors

Lung Cancer

Volumn 78, Issue 1, 2012, Pages 121-124

  Honda, Yoshihiro ^a   Takigawa, Nagio ^b   Fushimi, Soichiro ^a   Ochi, Nobuaki ^a,b   Kubo, Toshio ^a   Ozaki, Saeko ^a   Tanimoto, Mitsune ^a   Kiura, Katsuyuki ^a  

^a OKAYAMA UNIVERSITY HOSPITAL   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Cell line; Epidermal growth factor receptor; Large cell carcinoma; Non small cell lung cancer

Indexed keywords

AMRUBICIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; IRINOTECAN; PEMETREXED;

ADULT; ARTICLE; CASE REPORT; EXON; FEMALE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG NODULE; LYMPH NODE; LYMPH NODE BIOPSY; PLEURA EFFUSION; PRIORITY JOURNAL; SWELLING; TUMOR XENOGRAFT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84866174522     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.07.003     Document Type: Article

References (9)

1. Smith W., Khuri F.R. The care of the lung cancer patient in the 21st century: a new age. Semin Oncol 2004, 31:11-15.
2. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Branningan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
4. Gazdar A.F. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev 2010, 29:37-48.
5. Nogami N., Hotta K., Segawa Y., Takigawa N., Hosokawa S., Oze I., et al. Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402. Acta Oncol 2012, 51:768-773.
6. Gazdar A.F., Oie H.K. Re: Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res 1986, 46:6011-6012.
7. Nagai Y., Miyazawa H., Huqun, Tanaka T., Udagawa K., Kato M., et al. Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp. Cancer Res 2005, 65:7276-7282.
8. Oxnard G.R., Arcila M.E., Chmielecki J., Ladanyi M., Miller V.A., Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res 2011, 17:5530-5537.
9. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.